Literature DB >> 15482255

C and CX3C chemokines: cell sources and physiopathological implications.

Laura Stievano1, Erich Piovan, Alberto Amadori.   

Abstract

Within the fascinating world of chemokines, C and CX3C chemokines have long been regarded as two minor components, even though they present unique features and show less redundancy than the other chemokine families. Nevertheless, the body of data on their expression and role in various inflammatory disorders has grown in the past few years. The C chemokine family is represented by two chemokines, XCL1/lymphotactin-alpha and XCL2/lymphotactin-beta, whereas the CX3C chemokine family contains only one member, called CX3CL1/ fractalkine. In this review, we present an overview on the structure, expression and signaling properties of these chemokines and their respective receptors and examine how they contribute to inflammation and the regulation of leukocyte trafficking, as well as their potential role in the pathophysiology of human inflammatory diseases. Taken together, these data expand the biological importance of C and CX3C chemokines from that of simple immune modulators to a much broader biological role, even though their precise commitment within the framework of immune responses has still to be determined.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15482255     DOI: 10.1615/critrevimmunol.v24.i3.40

Source DB:  PubMed          Journal:  Crit Rev Immunol        ISSN: 1040-8401            Impact factor:   2.214


  34 in total

1.  Systemic and Mucosal Immune Responses to Cryptosporidium-Vaccine Development.

Authors:  Jacob G Ludington; Honorine D Ward
Journal:  Curr Trop Med Rep       Date:  2015-09-01

Review 2.  Genetic predisposition and renal allograft failure: implication of non-HLA genetic variants.

Authors:  Faisal Khan; Swati Agrawal; Suraksha Agrawal
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

3.  Norman Cousins Lecture. Glia as the "bad guys": implications for improving clinical pain control and the clinical utility of opioids.

Authors:  Linda R Watkins; Mark R Hutchinson; Annemarie Ledeboer; Julie Wieseler-Frank; Erin D Milligan; Steven F Maier
Journal:  Brain Behav Immun       Date:  2006-12-18       Impact factor: 7.217

Review 4.  Organ transplantation in rodents: novel applications of long-established methods.

Authors:  Peter Boros; Jianhua Liu; Yansui Li; Jonathan S Bromberg
Journal:  Transpl Immunol       Date:  2007-04-09       Impact factor: 1.708

Review 5.  "Listening" and "talking" to neurons: implications of immune activation for pain control and increasing the efficacy of opioids.

Authors:  Linda R Watkins; Mark R Hutchinson; Erin D Milligan; Steven F Maier
Journal:  Brain Res Rev       Date:  2007-07-13

6.  Immunoengineering nerve repair.

Authors:  Nassir Mokarram; Kyle Dymanus; Akhil Srinivasan; Johnathan G Lyon; John Tipton; Jason Chu; Arthur W English; Ravi V Bellamkonda
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-13       Impact factor: 11.205

7.  Adsorptive depletion of alpha4 integrin(hi)- and CX3CR1hi-expressing proinflammatory monocytes in patients with ulcerative colitis.

Authors:  Shin-ichiro Takeda; Toru Sato; Tatsuro Katsuno; Tomoo Nakagawa; Yoshiko Noguchi; Osamu Yokosuka; Yasushi Saito
Journal:  Dig Dis Sci       Date:  2009-11-12       Impact factor: 3.199

8.  Regulation of granulosa and theca cell transcriptomes during ovarian antral follicle development.

Authors:  Michael K Skinner; Michelle Schmidt; Marina I Savenkova; Ingrid Sadler-Riggleman; Eric E Nilsson
Journal:  Mol Reprod Dev       Date:  2008-09       Impact factor: 2.609

Review 9.  Cytokines and chemokines in neuropsychiatric syndromes of systemic lupus erythematosus.

Authors:  Hiroshi Okamoto; Akiko Kobayashi; Hisashi Yamanaka
Journal:  J Biomed Biotechnol       Date:  2010-06-29

10.  Elevated Fractalkine (CX3CL1) Levels in the Trigeminal Ganglion Mechanically Sensitize Temporalis Muscle Nociceptors.

Authors:  Brian E Cairns; Melissa O'Brien; Xu-Dong Dong; Parisa Gazerani
Journal:  Mol Neurobiol       Date:  2016-05-21       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.